Proteotype Diagnostics announced a new clinical study planned for Enlighten, its multicancer early detection test, to support CE-IVDR submission. The company is also initiating a separate study to optimize its platform, positioning itself for commercialization while preparing for additional funding to extend the regulatory and product-development phase.